Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation.

ABSTRACT:

Aims/hypothesis

Partial lipodystrophy (PL) is most commonly characterized by loss of subcutaneous fat in the extremities with preservation of truncal fat and is associated with insulin resistance, diabetes and hyperlipidaemia. Recombinant human leptin (r-metHuLeptin) therapy has been shown to be effective in treating metabolic abnormalities associated with congenital or acquired generalized lipodystrophy and PL associated with lamin A/C (LMNA) gene mutations or highly active antiretroviral therapy (HAART). Our aim was to assess the effectiveness of leptin therapy in treating metabolic complications of PL associated with heterozygous peroxisome proliferator activated receptor gamma (PPARG) mutations. This is the first report to detail the clinical response of a patient with PL due t

SUBMITTER: Guettier JM 

PROVIDER: S-EPMC2578870 | biostudies-literature | 2008 Apr

REPOSITORIES: biostudies-literature